Vitality Watch

Dossier clinicaltrials observational 05-oct-2026
Human cohort, case-control, or epidemiological association

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes

Key claim: A prospective descriptive study will track muscle mass, strength, physical performance, and sarcopenia risk at baseline and 3 months in non-diabetic obese adults starting GLP-1 RA therapy to relate weight loss to body-composition changes.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.

Why this matters

A prospective descriptive study will track muscle mass, strength, physical performance, and sarcopenia risk at baseline and 3 months in non-diabetic obese adults starting GLP-1 RA therapy to relate weight loss to body-composition changes.

Source

Link

Briefing card

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
Stage: observational · clinicaltrials · 05-oct-2026

A prospective descriptive study will track muscle mass, strength, physical performance, and sarcopenia risk at baseline and 3 months in non-diabetic obese adults starting GLP-1 RA therapy to relate weight loss to body-composition changes.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07858864

build build 880 · 2bcef25 · 2026-11-18